Whalegun
Home

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $30K for lobbying in Q2 2026 · Health Issues

Trade details

Type
Lobbying report
Amount
$30,000
Quarter
Q2 2026
Stock
Ultragenyx Pharmaceutical RARE
Client
Ultragenyx Pharmaceutical
Reported
26/07/20

Up 200.0% from last quarter

What else happened in Ultragenyx Pharmaceutical around then

Filed or reported within 30 days of the trade day · 05/31~07/30

Ultragenyx Pharmaceutical's other lobbying reports

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $30K for lobbying in Q2 2026 · Health Issues | Whalegun